Prognostic Significance of L-type Amino-acid Transporter 1 Expression in Surgically Resected Pancreatic Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Jul 19

PMID 22805328

Citations 100

Authors

K Kaira

Y Sunose

K Arakawa

T Ogawa

N Sunaga

K Shimizu

H Tominaga

N Oriuchi

H Itoh

S Nagamori

Y Kanai

A Segawa

M Furuya

M Mori

T Oyama

I Takeyoshi

Affiliations

Soon will be listed here.

Abstract

Background: The expression of L-type amino-acid transporter 1 (LAT1) is tumour-specific and has been shown to have essential roles in cell growth and survival. However, little is known regarding the clinical significance of LAT1 expression in pancreatic cancer. This study was conducted to determine the prognostic significance of LAT1 expression.

Methods: A total of 97 consecutive patients with surgically resected pathological stage I-IV pancreatic ductal adenocarcinoma were retrospectively reviewed. Tumour sections were stained by immunohistochemistry for LAT1, CD98, Ki-67 and vascular endothelial growth factor (VEGF), and microvessel density was determined by CD34 and p53.

Results: L-type amino-acid transporter 1 and CD98 were highly expressed in 52.6% (51/97) and 56.7% (55/97) of cases, respectively (P=0.568). The expression of LAT1 within pancreatic cancer cells was significantly associated with disease stage, tumour size, Ki-67, VEGF, CD34, p53 and CD98. L-type amino-acid transporter 1 expression was confirmed to be a significant prognostic factor for predicting poor outcome by multivariate analysis.

Conclusion: L-type amino-acid transporter 1 expression is a promising pathological marker for the prediction of outcome in patients with pancreatic cancer.

Citing Articles

Pharmacological and structural insights into nanvuranlat, a selective LAT1 (SLC7A5) inhibitor, and its N-acetyl metabolite with implications for cancer therapy.

Jin C, Zhou X, Xu M, Okanishi H, Ohgaki R, Kanai Y Sci Rep. 2025; 15(1):2903.

PMID: 39849059 PMC: 11758009. DOI: 10.1038/s41598-025-87522-6.

Identification of Metabolic Characteristic-Pancreatic Ductal Adenocarcinoma Associations Using Mendelian Randomization and Metabolomics.

Xiang Y, Zhang C, Wang J, Cheng Y, Wang K, Wang L J Gastrointest Cancer. 2025; 56(1):48.

PMID: 39833419 PMC: 11753325. DOI: 10.1007/s12029-025-01173-4.

A Review on the Role of Human Solute Carriers Transporters in Cancer.

Hossen M, Islam M, Yasin M, Ibrahim M, Das A Health Sci Rep. 2025; 8(1):e70343.

PMID: 39807482 PMC: 11725534. DOI: 10.1002/hsr2.70343.

Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives.

Hashimoto A, Hashimoto S Cancers (Basel). 2024; 16(23).

PMID: 39682280 PMC: 11640101. DOI: 10.3390/cancers16234094.

Amino acid transporter LAT1 is expressed on cancer cell-derived exosomes with potential as a diagnostic and prognostic biomarker.

Liu Y, Ohgaki R, Okanishi H, Xu M, Kanai Y Sci Rep. 2024; 14(1):28458.

PMID: 39557943 PMC: 11574015. DOI: 10.1038/s41598-024-79425-9.

References

DELCORE R, Rodriguez F, Forster J, HERMRECK A, Thomas J . Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg. 1996; 172(5):463-8; discussion 468-9. DOI: 10.1016/S0002-9610(96)00237-1. View

Cameron J, Riall T, Coleman J, Belcher K . One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006; 244(1):10-5. PMC: 1570590. DOI: 10.1097/01.sla.0000217673.04165.ea. View

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N . Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008; 98(4):742-8. PMC: 2259171. DOI: 10.1038/sj.bjc.6604235. View

Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N . High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int. 2011; 61(5):281-9. DOI: 10.1111/j.1440-1827.2011.02650.x. View

CHRISTENSEN H . Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990; 70(1):43-77. DOI: 10.1152/physrev.1990.70.1.43. View

Hellan M, Sun C, Artinyan A, Mojica-Manosa P, Bhatia S, Ellenhorn J . The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas. 2008; 37(1):19-24. DOI: 10.1097/MPA.0b013e31816074c9. View

Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A . Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999; 79(9-10):1553-63. PMC: 2362700. DOI: 10.1038/sj.bjc.6690248. View

Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T . Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2011; 103(2):382-9. DOI: 10.1111/j.1349-7006.2011.02151.x. View

von Forstner C, Zuhayra M, Ammerpohl O, Zhao Y, Tiwari S, Jansen O . Expression of L amino acid transport system 1 and analysis of iodine-123-methyltyrosine tumor uptake in a pancreatic xenotransplantation model using fused high-resolution-micro-SPECT-MRI. Hepatobiliary Pancreat Dis Int. 2011; 10(1):30-7. DOI: 10.1016/s1499-3872(11)60004-0. View

10.

Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T . L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 2009; 59(1):7-18. DOI: 10.1111/j.1440-1827.2008.02319.x. View

11.

Ahrendt S, Brown H, Komorowski R, Zhu Y, Wilson S, Erickson B . p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery. 2000; 128(4):520-30. DOI: 10.1067/msy.2000.108052. View

12.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N . CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol. 2009; 16(12):3473-81. DOI: 10.1245/s10434-009-0685-0. View

13.

Karamitopoulou E, Zlobec I, Tornillo L, Carafa V, Schaffner T, Brunner T . Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology. 2010; 42(3):229-34. DOI: 10.3109/00313021003631379. View

14.

Sun H, Qiu Z, Liu J, Sun J, Jiang T, Huang K . Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 2007; 30(6):1359-67. View

15.

Kaira K, Takahashi T, Abe M, Akamatsu H, Nakagawa K, Ohde Y . CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. Oncol Rep. 2010; 24(4):861-7. DOI: 10.3892/or.2010.861. View

16.

Geer R, Brennan M . Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165(1):68-72; discussion 72-3. DOI: 10.1016/s0002-9610(05)80406-4. View

17.

McGivan J, Pastor-Anglada M . Regulatory and molecular aspects of mammalian amino acid transport. Biochem J. 1994; 299 ( Pt 2):321-34. PMC: 1138275. DOI: 10.1042/bj2990321. View

18.

Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T . Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010; 28(23):3746-53. DOI: 10.1200/JCO.2009.27.4662. View

19.

Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K . Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004; 10(8):2846-50. DOI: 10.1158/1078-0432.ccr-02-1441. View

20.

Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S . Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2007; 451(3):681-90. DOI: 10.1007/s00428-007-0457-9. View